Home News DGAP-News: Sino European Biotechnology AG begins with research on mutations of the...

DGAP-News: Sino European Biotechnology AG begins with research on mutations of the H1N1 virus.


Release of a Corporate News, transmitted by DGAP – a company of EquityStory AG. For the content of Communication is the issuer / publisher responsible.
Frankfurt, 18 January 2009 – Sino European Biotechnology Ag ( ‘SEB’ or the "Company") (OTCBB: A0Q17H) brought an extensive research and developments relating to recently documented Deaths due to mutated forms of the H1N1 virus began.
H1N1 is a pandemic virus, in different strains is mutated. The current vaccines are effective in relation to the Main trunk of the H1N1 virus, but are ineffective in terms of new mutant strains considered. SEB AG is conducting research into an oral vaccine is effective against a variety of influenza strains including some new, mutated forms in the coming months and years could be more active. SEB AG hopes to clinical Testing can begin as soon as the specific vaccine developed.
According eTaiwan news’ spread of mutations Swine influenza virus in Europe like the French health authorities announced to leave while the World Health Organization (WHO) a surge caused by the disease-related deaths by more than 1,000 reported in a week.
Two patients infected with such a mutation has been had, which was recently discovered in Norway, in France died, said the Health Surveillance Institute of Government (InVS) in a statement.
This mutation could affect the ability of the virus, the Respiratory tract and affects in particular the lung tissue, . increase One of these patients the mutation from one another was Mutation accompanied by the one knows that they have an immunity for oseltamivir bring with them, he added, referring to thus on the medication used primarily to treat Swine influenza is used, and which is known under the brand name Tamiflu.
The WHO said that they investigate reports of Mutations of the virus, after half a dozen countries in such cases have registered.
‘The question now is whether these mutations suggest that a fundamental change in the virus in circulation takes place – whether in relation to the severity of the disease process change for Bad there, "said Keiji Fukuda, the Special Representative of the WHO pandemic influenza. "
Information on the SEB AG The Sino European Biotechnology AG is a biotechnology company with a large Presence in China. The company currently has 5 SFDA approved products and is currently in the research and Development of an oral vaccine) against H1N1 swine influenza. SEB AG uses the proprietary bioreactor process to many of their To produce products and is always looking for ways to improve the production of their products to people all over the world to send the best possible health care.
1. The primary objective of SEB is to provide all patients worldwide who Our products are taking the best treatment and Cures for a variety of diseases gain.
2. SEB intends to support the Chinese children, by using a different part of the profit Children’s Charity donates.
3. The researchers at SEB expand the frontiers of science in Service of humanity, with the aim of better health to grant. It is the mission of SEB, the champion of the Biotechnology and the advocate of its member organizations be as large as small.
The above information is also available online. Please Please also visit www.sinoeurobio.de
This press release contains certain statements that are as forward-looking statements’ can be considered. All statements in this Communication, which do not concern historical facts relating to future R & D activities, events or developments relate expected to SEB AG that they arrive, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, through the Words expects ‘,’ plan ‘,’ anticipates ‘, believes’, ‘intends’, ‘valued’
‘predicts’, ‘potential’ and similar expressions identified, or the fact that events or conditions will occur ‘, ‘would’,
‘may’, ‘could’ or ‘should’. Information concluded from the interpretation of different results be, may also considered forward-looking statements be, as they constitute a prediction of what is occurring could, when and if a product was actually developed.
Although the SEB AG believes that the expectations in such statements expressed expectations are based on reasonable assumptions, such statements are no guarantee of future performance and Actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results materially from those in the forward-looking statements that are R & D progress, successes and continued availability of capital and financing and general economic, market or business conditions.
Investors are cautioned that such statements are not guarantees are in favor of future performance and that actual Results or developments materially from those in the forward Statements may differ materially. Forward-looking statements are based on Opinions, estimates and opinions of management at SEB AG to Date on which the statements are made. SEB AG does not Obligation to update these forward-looking statements, should be the views, estimates or opinions Management or other factors change. No regulatory Authority has to the benefits of planned and proposed Transactions expressed or the content of this press release approved or rejected.
The source language, published in the original text is, is the official and authorized version. Translations be supplied for clarity. Only Language, which was published in the original, or otherwise. Therefore the same translation with the original language from the publication.
David Qi Sino European Biotechnology Leutschenbachstrasse 95 CH-8050 Zurich Switzerland
Phone: +41 (0) 44 308 39 91 Fax: +41 (0) 44 308 35 00 Email: info@sinoeurobio.com Website: www.sinoeurobio.de
18.01.2010 Ad-hoc news, financial news and Press releases transmitted by DGAP. Media archive at http://www.dgap-medientreff.de and http://www.dgap.de